HMOX1 and chronic thromboembolic pulmonary hypertension: Consequently, this suggests that STANNSOPORFIN has the potential to treat CTEPH by targeting HMOX1 to inhibit pulmonary smooth muscle cell and endothelial cell migration and abnormal proliferation.